Senomyx

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Stefan
Forum actieveling
Forum actieveling
Berichten: 475
Lid geworden op: 18 Dec 2012 18:52
Likes: 53
Contact:

Senomyx

Berichtdoor Stefan » 15 Jan 2013 11:19

http://markets.ft.com/research/Markets/ ... s=SNMX:NMQ" onclick="window.open(this.href);return false;

Huidige koers: $1.67
Koersdoel 2013: $ 5.70

Van dit aandeel wordt veel verwacht in 2013. Het advies is dan ook duidelijk: buy.
Biolase ($0.44)
Senomyx ($1.33)
Thrombogenics (€3,32)

Coins: Digibyte, Dogecoin, Reddcoin, Verge & Ripple.


rakara
Forum actieveling
Forum actieveling
Berichten: 397
Lid geworden op: 24 Feb 2012 12:13
Likes: 13
Contact:

Re: Senomyx

Berichtdoor rakara » 17 Jan 2013 17:46

Heb het eens bekeken: zware neerwaartse correctie geweest, nog steeds verlieslatend ondanks contracten met o.a. Pepsico.
Mag er beterschap verwacht worden?
Wat me ook tegenhoudt is dat het aandeel noteert aan 2.5 keer de boekwaarde ...
Iemand redenen waarom het aandeel terug zou kunnen stijgen?

Stefan
Forum actieveling
Forum actieveling
Berichten: 475
Lid geworden op: 18 Dec 2012 18:52
Likes: 53
Contact:

Re: Senomyx

Berichtdoor Stefan » 17 Jan 2013 19:21

http://www.marketwatch.com/story/senomyx-announces-approval-of-its-savory-flavors-and-s2383-flavor-ingredient-in-the-european-union-2012-10-09

The Savory Flavors and S2383 have been evaluated by the European Food Safety Authority (EFSA). On October 2, 2012 the European Commission published a regulation that adopts the Union List and permits usage of the named flavoring substances in the EU beginning in late-April 2013.


http://www.marketwatch.com/story/senomyx-receives-generally-recognized-as-safe-gras-determination-for-new-s9632-flavor-ingredient-2012-10-01

GRAS status allows S9632 to be used in a broad range of products in the U.S. and elsewhere

"S9632 provides Senomyx with an important new commercial opportunity," stated Kent Snyder, Chief Executive Officer of the Company. "The rising consumer focus on health and wellness has increased the demand for foods and beverages with reduced calories. S9632 is a solution for manufacturers seeking to create new offerings that meet this need, but retain the taste consumers enjoy."
Biolase ($0.44)
Senomyx ($1.33)
Thrombogenics (€3,32)

Coins: Digibyte, Dogecoin, Reddcoin, Verge & Ripple.

rakara
Forum actieveling
Forum actieveling
Berichten: 397
Lid geworden op: 24 Feb 2012 12:13
Likes: 13
Contact:

Re: Senomyx

Berichtdoor rakara » 18 Jan 2013 19:47

gisteren gekocht, vandaag nog wat opzoekingswerk: wat is er waar van dat artikel uit 2011 ivm stoffen afkomstig geaborteerde foetussen???!!! Iemand???

rakara
Forum actieveling
Forum actieveling
Berichten: 397
Lid geworden op: 24 Feb 2012 12:13
Likes: 13
Contact:

Re: Senomyx

Berichtdoor rakara » 06 Feb 2013 22:53

Knappe stijging vandaag: +11 %. Iemand een reden?

rakara
Forum actieveling
Forum actieveling
Berichten: 397
Lid geworden op: 24 Feb 2012 12:13
Likes: 13
Contact:

Re: Senomyx

Berichtdoor rakara » 16 Feb 2013 00:39

En we stijgen rustig verder! Iemand een reden?

faber2014
Forum newbie
Forum newbie
Berichten: 3
Lid geworden op: 29 Apr 2014 18:35
Likes: 0
Contact:

Re: Senomyx

Berichtdoor faber2014 » 05 Mei 2014 00:20

Senomyx is veel aan het inversteren de kosten daarvan zijn nu een nadeel, maar ik verwacht veel van dit aandeel de komende jaren. Aangezien Stevia de nieuwe suiker gaat worden. Het bevat geen calorieën en het is een natuurlijke suiker wie wil dat nou niet...

Stefan
Forum actieveling
Forum actieveling
Berichten: 475
Lid geworden op: 18 Dec 2012 18:52
Likes: 53
Contact:

Re: Senomyx

Berichtdoor Stefan » 28 Okt 2016 16:13

Senomyx (SNMX) Tops Q3 EPS by 2c

Senomyx (NASDAQ: SNMX) reported Q3 EPS of ($0.05), $0.02 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $6.02 million versus the consensus estimate of $5.36 million.

Financial Review and Outlook:

"Consistent with the first two quarters this year, Senomyx outperformed its financial guidance for the third quarter. We beat our net results guidance by over $600,000 driven by higher than anticipated commercial revenues and managing expenses to the low end of our internal target. Looking forward, we will continue to provide only quarterly guidance due to limited control over the timing of both commercial revenue growth and business development activities," Rogers concluded.

For the fourth quarter of 2016, the Company expects:
•Revenue to be at least $4.2 million, of which at least $2.3 million are commercial revenues; and
•Net loss not to exceed $4.5 million or $0.10 per share.

Regarding the Company's cash position, Senomyx ended the quarter with no debt and $15.7 million in cash. In addition, the Company is currently scheduled to receive $19.1 million in committed development funding payments of which $2.6 million will be received in the fourth quarter of 2016
Biolase ($0.44)
Senomyx ($1.33)
Thrombogenics (€3,32)

Coins: Digibyte, Dogecoin, Reddcoin, Verge & Ripple.

Stefan
Forum actieveling
Forum actieveling
Berichten: 475
Lid geworden op: 18 Dec 2012 18:52
Likes: 53
Contact:

Re: Senomyx

Berichtdoor Stefan » 31 Okt 2016 11:52

SENOMYX AND PEPSICO EXTEND SWEET TASTE PROGRAM COLLABORATION FOR THREE ADDITIONAL YEARS

SAN DIEGO, Sept. 30, 2016 /PRNewswire/ -- Senomyx, Inc. (SNMX) a leading company using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that it has amended and restated its Sweet Taste Program collaboration agreement with PepsiCo, Inc. The amendment extends PepsiCo's research funding for Senomyx's Natural Sweet Taste Program for three additional years, through September 2019.

Under the amended and restated agreement, Senomyx granted PepsiCo non-exclusive rights to natural sweeteners and natural flavor ingredients discovered, developed and selected under the collaboration for use in all non-alcoholic beverage categories. During the extension, Senomyx will be entitled to $18 million in research and development payments over the three-year research period. PepsiCo retains the option to further extend the research collaboration for two more years, which would result in additional research funding commitments. Senomyx will also be eligible for milestone payments based on the achievement of predetermined goals as well as royalty payments upon the sale of products containing natural sweeteners or ingredients selected under the collaboration.

"We are looking forward to continuing our collaboration with PepsiCo given our common objective of developing products that meet the growing demand for lower-calorie offerings," stated John Poyhonen, President and Chief Executive Officer of Senomyx. "PepsiCo is an industry leader, committed to reducing added sugar in their products and creating great tasting options for consumers."
Biolase ($0.44)
Senomyx ($1.33)
Thrombogenics (€3,32)

Coins: Digibyte, Dogecoin, Reddcoin, Verge & Ripple.

Stefan
Forum actieveling
Forum actieveling
Berichten: 475
Lid geworden op: 18 Dec 2012 18:52
Likes: 53
Contact:

Re: Senomyx

Berichtdoor Stefan » 04 Nov 2016 09:29


SENOMYX ANNOUNCES APPROVAL OF BITTERMYX® BB68 AND SWEETMYX® SR96 FLAVOR INGREDIENTS IN CHINA


SAN DIEGO, Aug. 31, 2016 PRNewswire/ -- Senomyx, Inc. (NASDAQ: SNMX), a leading company using proprietary taste science technologies to discover, develop and commercialize novel flavor ingredients for the food, beverage and flavor industries, announced today that its flavor ingredients Sweetmyx® SR96 (S9632) and Bittermyx® BB68 (S6821) have been approved for use by the Food and Drug Administration of the People's Republic of China. Sweetmyx SR96 is used to boost the sweet taste of products allowing food and beverage companies to significantly reduce sugar while maintaining the same taste to create lower calorie offerings. Bittermyx BB68 is used to reduce the bitterness of certain ingredients and can be used to reduce bitter taste associated with hydrolyzed soy and whey proteins, menthol, caffeine, cocoa, and Rebaudioside A (stevia) for use in food, beverage, OTC and oral care products.

"We are excited to announce the approval of these flavor ingredients in China," said John Poyhonen, President and Chief Executive Officer of Senomyx. "China is a very large market opportunity with a population exceeding 1.3 billion people and retail packaged food and beverage sales of approximately $600 billion annually1," Poyhonen noted. "These approvals also further validate our ability to attain approval by major regulatory bodies throughout the world."

This regulatory approval allows Senomyx to pursue commercialization of these flavor ingredients in China in a wide range of foods and beverages. These ingredients are available to flavor houses through Senomyx's direct sales Complimyx® line and can also be commercialized by two Senomyx collaborators in certain product categories.


About Senomyx, Inc. (http://www.senomyx.com)
Senomyx discovers novel flavor ingredients and natural high intensity sweeteners that allow food and beverage companies to create better-for-you products. Under its direct sales program, Senomyx sells its Complimyx® brand flavor ingredients, Sweetmyx®, Savorymyx®, and Bittermyx®, to flavor companies for use in a wide variety of foods and beverages. In addition, Senomyx has partnerships with leading global food, beverage, and ingredient supply companies, which are currently marketing products that contain Senomyx's flavor ingredients. For more information, please visit http://www.senomyx.com.
Biolase ($0.44)
Senomyx ($1.33)
Thrombogenics (€3,32)

Coins: Digibyte, Dogecoin, Reddcoin, Verge & Ripple.